Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrinolysis, Thrombolytic, Anti-Fibrotic, and Anti-Metastatic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PLG drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Glu-PLG) | Human PLG Recombinant Protein (Glu-form). Native zymogen conformation, >95% purity, Endotoxin <1 EU/µg, Sequence Verified. HEK293 expressed. | View PLG Products |
| Antigen Variant (Lys-PLG) | Human PLG (Lys-form / N-terminal Truncated). Open conformation mimic for activation studies. | View PLG Products |
| Mutant Panel | PLG Activation-Resistant Mutants (e.g., S741A). For mechanism studies, HEK293 expressed. | View PLG Products |
| Gene Delivery | PLG Promise-ORF / Lentivirus. Full-length ORF for stable secreted expression. | View PLG Products |
| Benchmark Ab | Anti-PLG Neutralizing Antibody (Research Grade). High affinity, species cross-reactive. | View PLG Products |
| Validator | PLG siRNA Set (3 unique sequences). For knockdown verification. | View PLG Products |
| Upstream Activator | PLAU (uPA/uPAR). Key activator complex for PLG conversion assays. | View PLAU Products |
| Pathway Inhibitor | SERPINE1 (PAI-1). Primary endogenous regulator for counter-screening. | View SERPINE1 Products |
| Related Target | PLAT (tPA). Primary physiological activator of Plasminogen. | View PLAT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Structural Conformation Stability | HEK293 Expressed (Native Glycosylation) ensuring proper folding. |
| Conformational State Discrimination (Closed Glu- vs Open Lys-) | Separate Glu-PLG (native) and Lys-PLG (N-truncated) proteins available, >95% pure, distinct epitope preservation for antibody screening. |
| Zymogen vs Active Plasmin Selectivity | Activation-resistant mutant panel (S741A, etc.) available for specific zymogen targeting without plasmin cross-reactivity. |
| Cross-species Preclinical Evaluation | Human, Mouse, and Cynomolgus orthologs available with sequence alignment >85%, endotoxin-controlled for in vivo models. |
| Fibrin Binding vs Cell Surface Binding | Native glycosylation pattern ensures authentic lysine-binding site (Kringle domains) conformation. |
| Activation Assay Reliability | High Purity (>95%) proteins with Endotoxin Controlled environments (<1 EU/µg). |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives | Validated siRNA included for specificity checks. |
Live PLG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The PLG therapeutic landscape is undergoing a paradigm shift from acute thrombolytic applications toward chronic disease modulation. While tissue-type Plasminogen Activator (tPA) remains the standard of care for ischemic stroke, next-generation R&D focuses on selective inhibition of extravascular plasminogen activation for fibrotic diseases (IPF, NASH) and metastatic cancer suppression. First-generation replacement therapies (e.g., Liminal BioSciences' Ryplazim) address congenital plasminogen deficiency (PLGD, often associated with known mutations such as rs73015965). The race for PLG therapeutics is intensifying, with major players shifting focus from traditional plasma-derived products to recombinant engineering and targeted modulators. As first-generation therapies reach the clinic for rare systemic deficiencies, the next wave of R&D is targeting localized fibrotic, ophthalmic, and hematological indications with highly engineered biologics. The known functional domains of PLG include the PAN domain and Kringle 1–2 (and Kringle 3–5), which are critical for fibrin binding and activation. Key mutations (e.g., rs73015965 in PLGD, rs1049573, rs4252070) inform the design of mutant panels for research.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Replacement Protein | Liminal BioSciences | Congenital Plasminogen Deficiency | Functional Activation Assay (Need high-purity protein) |
| Thrombolytic Biologics | Boehringer Ingelheim, Genentech | Acute Ischemic Stroke, Pulmonary Embolism | Fibrin-specific activation assays (Need native Glu-PLG substrate) |
| Anti-Fibrotic mAbs | Promedior (BMS), Lassen Therapeutics | IPF, Liver Fibrosis | Conformational Selectivity (Need Glu- vs Lys-PLG discrimination) |
| Metastasis Inhibitors | Multiple Biotechs | Solid Tumors | Cell Surface Binding (Need PLG-Annexin A2 interaction assays) |
| Small Molecule Inhibitors | Generic Manufacturers (TXA), Pharmaceutical Consortiums | Hemorrhage / Bleeding, Chronic Fibrosis | Receptor Binding / Zymogen Selectivity (Need exact structural conformation and activation-resistant mutants) |
| Monoclonal Antibody | Various Biopharma | Thrombosis / Fibrosis | Selectivity Assay (Need precisely mapped domains) |